26.30
-1.72%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Anglikang Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 002940.SZ. It has been listed since 23 October 2018. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.42bn and net income of CN¥125.4m. At that date it held total assets of CN¥2.95bn and shareholders' equity of CN¥1.63bn.
Zhejiang Anglikang Pharmaceutical Co., Ltd. engages in the research, development, production and sales of pharmaceutical drugs. The company is headquartered in Shaoxing, Zhejiang. The company went IPO on 2018-10-23. is a China-based company principally engaged in the research, development, production and sales of chemical raw materials and preparations. The firm's products mainly include cephalosporin and penicillin series, anti-hypertension series, digestive system series, kidney disease series and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Oct 2018
- Employees
- 981
- Website
- alkpharm.com ↗
Leadership
Pay as last reported
- Mr. Nanping FangChairman of the Board, since 2023CN¥802,100
- Ms. Songying MaoChief Financial Officer, Secretary of the BoardCN¥521,100
- Mr. Guogang ZhengGeneral Manager, Director, since 2023
- Mr. Huihao LuDeputy General Manager, Director
- Mr. Jinwen LuoDeputy General Manager
- Mr. Guodong YangDeputy General ManagerCN¥601,400
- Mr. Zhehua WuDirectorCN¥7.03bn
- Mr. Weimin MoIndependent DirectorCN¥100,000
- Mr. Hong YuanIndependent DirectorCN¥100,000
- Ms. Xiufang ZhaoIndependent DirectorCN¥100,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Anglikang Pharmaceutical employs 981 full-time employees in Shaoxing, China.
- The company focuses on cephalosporin and penicillin series pharmaceutical products.
- Zhejiang Anglikang Pharmaceutical has a strong presence in the Chinese pharmaceutical market.
Weaknesses
- Zhejiang Anglikang Pharmaceutical's business is limited to chemical raw materials and preparations in China.
- The company's product range includes only specific series like anti-hypertension and digestive system.
- Zhejiang Anglikang Pharmaceutical has no international market presence beyond China.
Opportunities
- Zhejiang Anglikang Pharmaceutical can expand its cephalosporin series in the Chinese market.
- The company may grow its anti-hypertension series within China's healthcare sector.
- Zhejiang Anglikang Pharmaceutical could develop new products in the kidney disease series.
Threats
- Zhejiang Anglikang Pharmaceutical faces competition from other Chinese pharmaceutical firms.
- The company's reliance on China's healthcare market poses a risk.
- Zhejiang Anglikang Pharmaceutical must navigate China's evolving pharmaceutical regulations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.